dexmedetomidine has been researched along with Neurodegenerative Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badulescu, AV; Burlacu, CC; Buzoianu, AD; Mitre, AO; Neag, MA; Sirbu, AC | 1 |
| Ewing, L; Hofacer, RD; Joseph, B; Lee, JR; Lee, SY; Lin, EP; Loepke, AW; Upton, B | 1 |
| Dong, G; Ebrahimnejad, A; Koo, E; Meschter, C; Oshodi, T | 1 |
| Han, F; Liu, Z; Ning, Q; Sun, H; Wang, X; Yang, M; Zhang, J; Zhang, R; Zhang, X; Zhao, W | 1 |
1 review(s) available for dexmedetomidine and Neurodegenerative Diseases
| Article | Year |
|---|---|
The Role of miRNAs in Dexmedetomidine's Neuroprotective Effects against Brain Disorders.
Topics: Anesthetics; Brain Injuries, Traumatic; Dexmedetomidine; Humans; MicroRNAs; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxicity Syndromes | 2022 |
3 other study(ies) available for dexmedetomidine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Alternative technique or mitigating strategy for sevoflurane-induced neurodegeneration: a randomized controlled dose-escalation study of dexmedetomidine in neonatal rats.
Topics: Anesthetics, Inhalation; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hypnotics and Sedatives; Neurodegenerative Diseases; Random Allocation; Rats; Rats, Wistar; Sevoflurane | 2017 |
Neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Brain; Caspase 3; Dexmedetomidine; Dose-Response Relationship, Drug; Female; Hypnotics and Sedatives; Ketamine; Macaca fascicularis; Maternal-Fetal Exchange; Neurodegenerative Diseases; Prefrontal Cortex; Pregnancy | 2014 |
Neurodegenerative changes and neuroapoptosis induced by systemic lipopolysaccharide administration are reversed by dexmedetomidine treatment in mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Brain; Brain Diseases; Dexmedetomidine; Disease Models, Animal; Interleukin-1beta; Lipopolysaccharides; Male; Malondialdehyde; Mice, Inbred BALB C; Neurodegenerative Diseases; Neuroimmunomodulation; Neurons; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Reactive Oxygen Species; Sepsis; Tumor Necrosis Factor-alpha | 2017 |